Navigation Links
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
Date:7/1/2008

The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston. Findings were published online on June 29 by the journal Nature Biotechnology.

Because it is nontoxic and can be taken orally, the drug, called Lodamin, may be useful as a preventive therapy for patients at high risk for cancer or as a chronic maintenance therapy for a variety of cancers, preventing tumors from forming or recurring by blocking the growth of blood vessels to feed them. Lodamin may also be useful in other diseases that involve aberrant blood-vessel growth, such as age-related macular degeneration and arthritis.

Developed by Ofra Benny, PhD, in the Children's laboratory of the late Judah Folkman, MD, Lodamin is a novel slow-release reformulation of TNP-470, a drug developed nearly two decades ago by Donald Ingber, MD, PhD, then a fellow in Folkman's lab, and one of the first angiogenesis inhibitors to undergo clinical testing. In clinical trials, TNP-470 suppressed a surprisingly wide range of cancers, including metastatic cancers, and produced a few complete remissions. Trials were suspended in the 1990s because of neurologic side effects that occasionally occurred at high doses, but it remains one of the broadest-spectrum angiogenesis inhibitors known.

Lodamin appears to retain TNP-470's potency and broad spectrum of activity, but with no detectable neurotoxicity and greatly enhanced oral availability. While a number of angiogenesis inhibitors, such as Avastin, are now commercially available, most target only single angiogenic factors, such as VEGF, and they are approved only for a small number of specific cancers. In contrast, Lodamin prevented capillary growth in response to every angiogenic stimulus tested. Moreover, in mouse models, Lodamin reduced liver metastases, a fatal complication of many cancers for which
'/>"/>

Contact: Bess Andrews
elizabeth.andrews@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
2. New inhibitor has potential as cancer drug
3. New research shows no link between aromatase inhibitors and cardiovascular problems
4. New partnership offers outsourced R&D in membrane biology
5. Census of protein architectures offers new view of history of life
6. NAS report offers new tools to assess health risks from chemicals
7. New class of drug offers hope to treatment-resistant AIDS patients
8. Darwin Symposium at Field Museum offers broad overview of his science and its impact
9. Conference on healthspan offers new opportunities for interdisciplinary collaboration
10. Protein controls blood vessel formation, offers new drug target
11. Genetic breakthrough offers promise in tackling kidney tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
(Date:8/21/2014)... landmark study aimed at improving the food intake, health ... care homes is among three projects at the University ... from the Canadian Institutes of Health Research (CIHR). ... Health Sciences at Waterloo, and a Schlegel research chair ... years to investigate why many Canadians living in long-term ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2Water window imaging opportunity 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... Journal of Animal Science , researchers evaluated how different levels ... to the researchers, the effects of selenium supplementation on the ... extensively in horses. Dr. Laurie Lawrence, animal science professor ... in soil and forages varies across the United States. She ...
... of consuming omega-3 long chain polyunsaturated fatty acids such ... sources of these fatty acids in the human diet ... of Saskatchewan, Department of Animal and Poultry Science are ... of farmed fish. As wild fish stocks ...
... reporting "a significant step forward" in proving the feasibility of ... for exotic new life forms. Their description of successful deployment ... seafloor lander equipped with a mini-laboratory the size of a ... of DNA in the deep oceans appears in ACS, ...
Cached Biology News:Researchers study selenium's effects on horses 2
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies Corp. ... developing first in class collagenase-based products marketed as ... in the U.S. and XIAPEX ® in ... from a randomized, double-blind Phase 2a study of ... edematous fibrosclerotic panniculopathy. The results showed that all ...
(Date:8/21/2014)... research team including DESY scientists has observed tiny quantum ... reports in the journal Science that the ... the nanodroplets. It is the first time that the ... samples of what is known as superfluid helium, have ... best expectations," says Andrey Vilesov of the University of ...
(Date:8/21/2014)... IA (PRWEB) August 21, 2014 His ... LIBERTY Opening , The Court of His Majesty Willem-Alexander, ... will attend the Grand Opening of POET-DSM Advanced Biofuels’ ... Wednesday, Sept. 3. , The King will take part ... opening activity, scheduled for 11 a.m.-12:20 p.m. and tour ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Fla., April 14 Phlo Corporation,(Pink Sheets: PHCP) ... stock certificates are negotiable in connection with,market transactions ... current,position in Phlo common stock. This clarification was ... number of brokers and clearing firms,will not negotiate ...
... in the second quarter of 2008 ... ... Ardea,Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data ... compounds demonstrating potent,activity against the human-immunodeficiency virus (HIV), including NNRTI-,resistant strains, with ...
... basis of blood-based ColonSentry(TM) test -, TORONTO, ... company focused on developing blood-based biomarker tests for ... today reported,positive performance results from a large validation ... of a patient,s current risk for,colorectal cancer. This ...
Cached Biology Technology:Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 3GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
... ventilated and BR4i refrigerated multifunction centrifuges are equally ... at a low sound level with a large ... Their AUTO-LOCK rotor exchange system without tools ensures ... within seconds. Instant rotor exchange (5 ...
Biology Products: